Target intelligence / Profile preview

Matrix metalloproteinase 12 (MMP-12)

Target
MMP-12
Molecular classification
Enzyme, Matrix metalloproteinase (MMP family), Metallopeptidase
01

Overview

Matrix metalloproteinase 12 (MMP-12), also known as macrophage metalloelastase, is a zinc-dependent endopeptidase in the matrix metalloproteinase family, primarily secreted by macrophages[1][2]. MMP-12 plays a crucial role in the degradation of extracellular matrix proteins, especially elastin, during physiological processes such as tissue remodeling, embryonic development, and reproduction, and in pathological conditions including atherosclerosis, aneurysm, emphysema, arthritis, and tumor metastasis[1][2][3]. High MMP-12 expression is associated with advanced atherosclerotic plaques, plaque vulnerability, and the promotion of apoptosis in plaque macrophages, contributing to disease progression and instability[3]. It is a validated therapeutic target for several diseases with tissue remodeling and inflammatory components, but clinical targeting is limited by broad MMP inhibitor toxicity[2][3].

Other names
macrophage metalloelastasemacrophage elastaseMMEME
02

Mechanism of action

Inhibition of proteolytic (elastolytic) activity to prevent extracellular matrix degradation and tissue remodeling

03

Biological functions

Breakdown of extracellular matrixElastin degradationTissue remodelingEmbryonic developmentReproductionRegulation of cell migration, proliferation, and apoptosisInflammatory response
04

Disease associations

Cardiovascular disease (e.g., atherosclerosis, aneurysm formation, vascular invasion)Pulmonary disease (e.g., pulmonary emphysema, chronic obstructive pulmonary disease)Cancer (e.g., hepatic cell carcinoma, tumor invasion and metastasis)Inflammation (e.g., arthritis)
05

Safety considerations

Potential issues with broad-spectrum MMP inhibition leading to impaired tissue remodeling and adverse connective tissue effects (musculoskeletal syndrome, poor wound healing)Increased infection risk due to suppressed immune cell migration and function
06

Interacting drugs

As of current knowledge, no specific clinically approved drug directly targets MMP-12, but broad-spectrum and investigational MMP inhibitors (e.g., marimastat, batimastat) have MMP-12 as part of their profile
07

Biomarkers

MMP-12 protein levels may serve as a biomarker for plaque vulnerability in atherosclerosisMMP-12 is under investigation as an adverse prognostic biomarker for vascular invasion in hepatic cell carcinoma

Beyond the preview

Go deeper on Matrix metalloproteinase 12 (MMP-12).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Matrix metalloproteinase 12 (MMP-12).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call